Assessment of medication adherence and quality of life and their association with myocardial infarction during percutaneous coronary intervention
DOI:
https://doi.org/10.18203/2319-2003.ijbcp20261956Keywords:
Myocardial infarction, PTCA, Quality of life , Medication adherenceAbstract
Background: Myocardial infarction (MI) patients undergoing percutaneous coronary intervention (PCI) require careful management. Medication adherence and quality of life (QOL) are crucial for preventing future cardiovascular events. Optimizing these factors improves patient outcomes and long-term health.
Methods: This prospective observational study was conducted over six months in omini hospital, Kurnool. A total of 70 hypertensive CKD patients were enrolled and divided into two groups: Group A received Cilnidipine 10 mg daily, and group B, received Telmisartan 40 mg daily. Patients were evaluated for changes in renal in systolic and diastolic blood pressure, renal function markers (serum creatinine, urea, uric acid, proteinuria), and incidence of adverse effects.
Results: MI as a leading cause of death in India, predominantly affecting men aged 51-60 due to factors like changing lifestyles, dietary habits, family history, and social behaviors.
Conclusions: MI has emerged as a major cause of mortality in India, particularly affecting men in the 51-60 age range due to shifting dietary patterns, sedentary lifestyles, genetic predispositions, and social habits. Patients treated with PTCA, in accordance with American Heart Association protocols, showed noticeable improvement in their QOL after a four-month follow-up, with male participants reporting more substantial progress compared to females. Medication adherence evolved positively especially among male patients in the target age group. This study emphasizes that stronger medication compliance plays a key role in enhancing post-treatment QOL.
References
Thygesen K, Alpert JS, Jaffe AS, Chaitman BR, Bax JJ, Morrow DA, et al. Fourth Universal Definition of Myocardial Infarction (2018). Eur Heart J. 2019;40(3):237-69.
Amsterdam EA, Wenger NK, Brindis RG, Casey DE Jr, Ganiats TG, Holmes DR Jr, et al. 2014 AHA/ACC Guideline for the Management of Patients with Non–ST-Elevation Acute Coronary Syndromes. Circulation. 2014;130(25):e344-426.
Mayo Clinic. Heart attack-Symptoms and causes. Available at: mayoclinic.org. Accessed on 20 February 2026.
Canto JG, Rogers WJ, Goldberg RJ, Peterson ED, Wenger NK, Vaccarino V, et al. Association of age and sex with myocardial infarction symptom presentation and in-hospital mortality. JAMA. 2012;307(8):813-22.
O'Gara PT, Kushner FG, Ascheim DD, Casey DE Jr, Chung MK, de Lemos JA, et al. 2013 ACCF/AHA Guideline for the Management of ST-Elevation Myocardial Infarction. Circulation. 2013;127(4):e362-425.
Thygesen K, Alpert JS, Jaffe AS, Chaitman BR, Bax JJ, Morrow DA, et al. Fourth Universal Definition of Myocardial Infarction. J Am Coll Cardiol. 2018;72(18):2231-64.
Chow CK, Jolly S, Rao-Melacini P, Fox KA, Anand SS, Yusuf S. Association of diet, exercise, and smoking modification with risk of early cardiovascular events after acute coronary syndromes. Circulation. 2010;121(6):750-8.
Ibanez B, James S, Agewall S, Antunes MJ, Hector B, Bucciarelli DC, et al. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur Heart J. 2018;39(2):119-77.
O'Gara PT, Kushner FG, Ascheim DD, Casey DE Jr, Chung MK, de Lemos JA, et al. 2013 ACCF/AHA Guideline for the Management of ST-Elevation Myocardial Infarction. Circulation. 2013;127(4):e362-425.
Kini V, Ho PM. Interventions to Improve Medication adherence: A Review. JAMA. 2018;320(23):2461-73.
Yusuf S, Hawken S, Ounpuu S, Dans T, Avezum A, Lanas F, et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (INTERHEART study). Lancet. 2004;364(9438):937-52.
World Health Organization. Cardiovascular diseases (CVDs). Geneva: WHO. 2023.
American Heart Association. Heart disease and stroke statistics-2023 update. Circulation. 2023;147:e93-621.
Reed GW, Rossi JE, Cannon CP. Acute myocardial infarction. Lancet. 2017;389(10065):197-210.
European Society of Cardiology. ESC Guidelines for acute coronary syndromes. Eur Heart J. 2023.
Brown MT, Bussell JK. Medication adherence: WHO cares? Mayo Clin Proc. 2011;86(4):304-14.
Ho PM, Bryson CL, Rumsfeld JS. Medication adherence: its importance in cardiovascular outcomes. Circulation. 2009;119(23):3028-35.
Chowdhury R, Khan H, Heydon E, Shroufi A, Mozaffarian D, Capewell S, et al. Adherence to cardiovascular therapy: a meta-analysis of prevalence and clinical consequences. Eur Heart J. 2013;34(38):2940-8.
Vrijens B, De Geest S, Hughes DA. A new taxonomy for describing and defining adherence to medications. Br J Clin Pharmacol. 2012;73(5):691-705.
Lam WY, Fresco P. Medication adherence measures: an overview. Biomed Res Int. 2015;2015:217047.
Thompson K, Kulkarni J, Sergejew AA. Reliability and validity of a new Medication Adherence Rating Scale (MARS). Schizophr Res. 2000;42(3):241-7.
Molloy GJ, Messerli-Bürgy N, Hutton G, Wikman A, Perkins-Porras L, Steptoe A, et al. Age and medication adherence after myocardial infarction. Int J Cardiol. 2014;172(1):e1-3.
Jimmy B, Jose J. Patient medication adherence: measures in daily practice. Oman Med J. 2011;26(3):155-9.
Kini V, Ho PM. Interventions to improve medication adherence. JAMA. 2018;320(23):2461-73.
Braunwald E. Braunwald’s Heart Disease: A Textbook of Cardiovascular Medicine. 12th ed. Philadelphia: Elsevier. 2022.
American College of Cardiology/American Heart Association guideline on secondary prevention after myocardial infarction. Circulation. 2019.
Levine GN, Bates ER, Bittl JA, Brindis RG, Bove FA, Byrne JC, et al. 2016 ACC/AHA guideline focused update on duration of dual antiplatelet therapy in coronary artery disease patients. Circulation. 2016;134:e123-55.
Downloads
Published
How to Cite
Issue
Section
